CTIS2022-501518-67-00招募中1 期
SUrGery with or without dARolutamide in high-risk and/or locally advanced prostate cancer - 22GENH03
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- Male
入选标准
- •1.Age =18 years, 10.Life expectancy more than 5 years, 11.Men engaged in sexual activity with a woman of childbearing potential should accept (or female partners of men enrolled in the study who are of childbearing potential or are pregnant) to use an highly effective contraception during darolutamide treatment and at least one week after the end of the investigational product, 12.Signed informed consent, 13.Patient able to participate and willing to give informed consent prior performance of any study-related procedures and to comply with the study protocol for the duration of the study, including undergoing treatment and scheduled visits and examinations including follow up, 14.Patient affiliated to a Social Health Insurance in France., 2.Histologically confirmed adenocarcinoma of the prostate, 3.High-risk and/or locally advanced prostate cancer diagnosis defined by: One of the following criteria is sufficient to define a high-risk and/or locally advanced prostate cancer: -ISUP grade 4 or 5 on biopsies -cN1 disease in MRI or PET-Scan -T3b disease in MRI If these criteria are not being identified, two of the following criteria are necessary to define high-risk and/or locally advanced prostate cancer: -PSA value >20 ng/ml -= 50% of the core of biopsies need to be positive for adenocarcinoma ISUP grade 3 -T3a disease in MRI, 4.No distant metastasis confirmed by imaging (i.e., MRI/CT-Scan and Bone Scintigraphy or PET-Scan), 5.Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0-1, 6.Patient eligible for radical prostatectomy as per the investigator, 7.Adequate organ function within 28 days prior to start of treatment determined by the following central laboratory values: -Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin less than the upper limit of normal (ULN; note that in subjects with Gilbert’s syndrome, if total bilirubin is >1.5 X ULN, measure direct and indirect bilirubin. If direct bilirubin is =1.5 X ULN, the subject may be eligible); -Serum creatinine <1.5 mg/dL; -Platelets =75,000/uL, without transfusion and/or growth factors within 1 month prior to randomization; -Hemoglobin >12.0 g/dL (7.4 mmol), without transfusion and/or growth factors within 1 month prior to randomization; -Adequate renal function: creatinine clearance/eGFR within normal limits to baseline assessed as per local standard method; -Normal cardiac function according to local standard by 12-lead Electrocardiogram (ECG) (complete, standardized 12-lead recording)., 8.Patient able to receive darolutamide for up to 9 months, as per the investigator, 9.Patient able to swallow whole study drug tablets
排除标准
- •1.Distant metastasis (clinical stage M1). Nodal disease below the iliac bifurcation (clinical stage N1) is not an exclusion., 3.Prior treatment for prostate cancer, 4.Castrated men (Bilateral orchiectomy or other), 5.History of any pelvic radiation, 6.Any of the following concurrent illness within 6 months prior to first dose of study drug: severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (eg., pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias or New York Heart Association Class II to IV heart disease; uncomplicated deep vein thrombosis is not considered exclusionary, 7.Uncontrolled hypertension as indicated by a systolic blood pressure (BP) = 160 mmHg or diastolic BP = 100 mmHg at screening despite medical management. Participants with hypertension can enroll provided BP is stable and controlled by anti-hypertensive treatment, 8.HIV-positive patient with one or more of the following: Not receiving highly active antiretroviral therapy; Had a change in antiretroviral therapy within 6 months of the start of screening; Receiving antiretroviral therapy that may interfere with study drug; CD4 count <350 at screening; AIDS-defining opportunistic infection within 6 months of start of screening, 9.Active or symptomatic viral hepatitis or chronic liver disease; ascites or bleeding disorders secondary to hepatic dysfunction, 17. Patients with a history of another malignancy at high risk of recurrence within 5 years and with a concurrent malignancy requiring active treatment or having required anticancer treatment within 6 months prior to inclusion, 10.Gastrointestinal conditions affecting absorption, 11.Known or suspected contraindications or hypersensitivity to darolutamide, 12.Treatment with strong CYP3A4 inducers and/or P-gp inducers within 2 weeks or 5 drug-elimination half-lives, whichever is longer, prior to initiation of study drug, 13.Major surgery within 28 days before first dose of study treatment, 14.Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure, 15.Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice), 16.Concurrent enrolment in another interventional therapeutic clinical study, 2.Pathological finding consistent with small cell, ductal or neuroendocrine carcinoma of the prostate
研究者
相似试验
进行中（未招募）
2 期
SUrGery With or Without dARolutamide in High-risk and/or Locally Advanced Prostate CancerProstate CancerNCT05826509Institut Claudius Regaud240
进行中（未招募）
1 期
DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer.CTIS2024-514565-18-00Cancer Trials Ireland1,107
进行中（未招募）
1 期
A clinical research study to investigate whether the addition of a new medication (darolutamide) to standard treatment is better for improving the outcomes for men with localised prostate cancer compared to standard treatment.Clinically localised prostate cancer defined as very high risk, or with very high risk features.MedDRA version: 20.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-004818-34-IECancer Trials Ireland1,100
进行中（未招募）
不适用
A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are DescribedProstate CancerNCT04122976Bayer805
进行中（未招募）
3 期
Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate CancerProstatic NeoplasmsNCT04736199Bayer669